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Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology
through the neurokinin G protein-coupled receptor family, implicated in a diverse array of
pathological processes. Here we report high-resolution crystal structures of the human NK1
receptor (NK1R) bound to two small-molecule antagonist therapeutics – aprepitant and
netupitant and the progenitor antagonist CP-99,994. The structures reveal the detailed
interactions between clinically approved antagonists and NK1R, which induce a distinct
receptor conformation resulting in an interhelical hydrogen-bond network that cross-links the
extracellular ends of helices V and VI. Furthermore, the high-resolution details of NK1R bound
to netupitant establish a structural rationale for the lack of basal activity in NK1R. Taken
together, these co-structures provide a comprehensive structural basis of NK1R antagonism
and will facilitate the design of new therapeutics targeting the neurokinin receptor family.
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The neurokinin (NK) receptor-ligand system represents acomplex, evolutionarily conserved neuropeptide signalingarchitecture1,2. Derived from alternate processing of two
genes, the best-characterised mammalian neurokinins are Sub-
stance P (SP), NKA and NKB, sharing the conserved C-terminal
structural motif FxGLM-NH23. Among other neurokinins, these
three peptides act as agonists with different afﬁnities and selec-
tivity for three pharmacologically distinct neurokinin receptors4
(NK1R, NK2R and NK3R) that belong to the superfamily of
G protein-coupled receptors (GPCRs). Within this system, SP
represents the preferred endogenous agonist of NK1R4. NK1R
has been shown to be present in the central and peripheral ner-
vous system5,6, smooth muscle7, endothelial cells8 and also
on cells that participate in the immune response9. Over the past
four decades, intensive research has linked the SP-NK1R
system to such diverse pathophysiological processes as nausea10,
analgesia11,12, inﬂammation13, pruritus14 and depression15,16,
highlighting the potential therapeutic value of antagonists direc-
ted against NK1R. This prospect triggered widespread efforts
across industry and academia to discover such compounds to
date17,18.
Disclosure of the ﬁrst non-peptide NK1R antagonist CP-
96,34519 (Supplementary Figure 1), discovered by high-
throughput screening (HTS), subsequently spurred the develop-
ment of a number of antagonists with improved pharmacological
properties. This led to the identiﬁcation of CP-99,99420, which
reduced the chemical structure of CP-96,345 to a molecular
scaffold found in many later-stage small-molecule antagonists.
CP-99,994 displays high afﬁnity and selectivity for NK1R, as well
as efﬁcacy in animal models, and therefore historically provided a
valuable pharmacological tool for the investigation of the phy-
siological role of SP-mediated signaling through NK1R21. Mod-
iﬁcation of the central saturated six-membered piperidine ring
of CP-99,994 alongside further scaffold optimisations22,23 (by
substituent addition and modiﬁcations) ultimately lead to the
development of aprepitant24 (Supplementary Figure 1), which
became the ﬁrst approved oral drug to make it into the clinic,
speciﬁcally targeting NK1R for the treatment of chemotherapy-
induced nausea and vomiting (CINV)25. Over the past four years,
two further molecules (i.e. netupitant and rolapitant) that do not
share the common chemical scaffold of these earlier antagonists
have been approved for use in the clinic for the same indication17.
Extensive structure-activity relationship (SAR) studies per-
formed over the course of three decades have revealed insights
into overlapping and non-overlapping binding sites involved in
recognition of peptide agonists and non-peptide antagonists in
NK1R26–28. However, until now, little has been known about
the precise binding mode of small-molecule antagonists to NK1R
in the absence of a structure of this receptor. Since the proto-
typical antagonist CP-99,994 already displays many chemical
features that are relatively preserved in further developed com-
pounds we initially solved the structure of NK1R in complex with
this ligand. We then went on to co-crystallise NK1R with two
FDA-approved drugs—aprepitant and netupitant.
Here, we report three crystal structures of the human NK1R
bound to CP-99,994 and the clinically approved antagonists
aprepitant and netupitant at 3.27, 2.40 and 2.20 Å resolution,
respectively. These structures provide detailed and high-
resolution structural insights into the molecular determinants of
NK1R antagonist recognition. The clinically approved antagonists
are able to invoke structural rearrangements in the orthosteric
binding pocket at the extracellular ends of helices V and VI and
the extracellular loops (speciﬁcally ECL2) that govern the overall
size and nature of the pocket, thereby acting to negatively mod-
ulate the receptor via an induced-ﬁt binding mechanism. The
observed high degree of plasticity in the NK1R orthosteric binding
pocket across the three structures reported here vastly improves
our structural knowledge of NK1R, explaining the different
properties of current inhibitors and potentially facilitating the
future development of ligands selectively targeting various NK
receptors.
Results
Crystallisation of antagonist-bound NK1R. To improve protein
expression, and ultimately the yield of NK1R preparations, two
consecutive rounds of directed evolution in Saccharomyces cere-
visiae were initially performed on the human NK1R29. One
evolved receptor mutant (NK1R-y04) was further thermo-
stabilised in an antagonist-bound state through incorporation of
four amino acid substitutions, L742.46A, A1444.39L, A2155.57L
and K2436.30A (Ballesteros and Weinstein numbering30 denoted
in superscript), leading to NK1RS (Methods and Supplementary
Figure 2a, b). To facilitate crystallisation in lipidic cubic phase,
11 residues (E227-H237) of the third intracellular loop (ICL3)
were replaced by the thermostable PGS (Pyrococcus abysii gly-
cogen synthase) domain31. The crystallised PGS fusion construct
NK1RXTAL is able to bind all co-crystallised antagonists with low
nanomolar afﬁnity. However, ligand afﬁnity is reduced ∼10-fold
when compared to the wild-type receptor, possibly due to an
increased rigidity of the stabilised fusion construct (Supplemen-
tary Table 1). For crystallisation in lipidic cubic phase, NK1RXTAL
was puriﬁed from Spodoptera frugiperda (Sf9) insect cell mem-
branes in the presence of either CP-99,994, aprepitant or netu-
pitant. We then crystallised and determined three crystal
structures of NK1R bound to three different antagonists, com-
plexed with CP-99,994 at 3.27 Å resolution, aprepitant at 2.40 Å
resolution and ﬁnally with netupitant at 2.20 Å resolution
(Table 1), with strong and unambiguous electron density for
each antagonist present in the orthosteric site as well as key
interaction residues of the receptor (Fig. 1d–f and Supplementary
Figure 3d–i).
While NK1R in complex with CP-99,994 crystallised in space
group C2221 (Supplementary Figure 4b, d–f), it is noteworthy
that crystallisation of NK1R with both aprepitant and netupitant
consistently lead to better diffracting crystals in a different
condition belonging to space group P212121 (Supplementary
Figure 4c, g–i). However, attempts to switch crystallisation
conditions, i.e. crystallisation of NK1R with CP-99,994 in those
speciﬁc to netupitant or aprepitant, were not successful,
indicating that the receptor conformations described here are
speciﬁc to the ligands with which they are crystallised.
Overall architecture of NK1R. Overall, NK1R exhibits the
canonical GPCR architecture comprising seven transmembrane
helices (I–VII) with helix 8 lying parallel to the membrane plane
(Fig. 1a–c). All intracellular and extracellular loops (ICLs and
ECLs, respectively) are well resolved with the exception of ECL3.
In NK1R, similar to other structures of the β-branch of class A
GPCRs, ECL2 forms an extended β-hairpin crossing above the
orthosteric pocket and is anchored to the extracellular tip of helix
III through a conserved disulﬁde bridge between C180ECL2 and
C1053.25.
The structure of the transmembrane helical bundle of NK1R is
similar to those of other receptors from the β-branch of class A
GPCRs bound to small-molecule antagonists, with root-mean-
square deviations (RMSD) for backbone atoms of 1.3 Å to orexin
2 receptor31 (OX2R) (PDB ID 4S0V), 1.4 Å to neuropeptide Y Y1
receptor32 (Y1R) (PDB ID 5ZBH) and 2.5 Å to endothelin B
receptor33 (ETBR) (PDB ID 5XPR) (Supplementary Figure 5a–i).
In the three NK1R structures, the highly conserved residue
W2616.48, which has been reported as the “toggle switch”
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important in triggering GPCR activation34, is in a similar
conformation to those observed in other inactive class A GPCR
structures. Furthermore, the “ionic lock” involving R3.50 of the D/
ERY motif, making an intrahelical salt bridge with D3.49, is
present in all solved NK1R structures. Taken together, the NK1R
structures in complex with different antagonists capture the
inactive receptor conformation.
The NK1R orthosteric antagonist binding pocket. In all three
NK1R co-structures, the antagonist small molecules are found
buried within a largely hydrophobic cleft constituting the
orthosteric binding pocket. The binding site is characterised by
being elongated on a trajectory between helices II and IV and
laterally constricted by side chains of helices III and VI (Fig. 1d–f
and Supplementary Figure 6a–c). Although the overall shape of
the NK1R orthosteric binding pocket is itself unique, its depth
and overall location within the transmembrane helical bundle is
comparable to those in previously reported closely related
structures, conﬁrming that the non-peptide NK1R small molecule
antagonists occupy at least in part the typical drug-binding site of
peptide-activated receptors (Supplementary Figure 5a–i).
Most high-afﬁnity NK1R-selective antagonists are characterised
by a common pharmacophore. In general, this structural
framework consists of a central six-membered ring with two
(and in later-stage compounds three) bulky substituents
(Fig. 2d–f). Henceforth, and for clarity, the central ring is termed
the “core”, the linker-attached bulky aromatic group (i.e. the
methoxyphenyl group in CP-99,994 or di-triﬂuoromethylphenyl
in all other antagonists) “arm 1” and the directly attached
aromatic moiety (i.e. the phenyl in CP-99,994 or ﬂuorophenyl
in aprepitant or methylphenyl in netupitant) “arm 2”. The
additional variable cyclic substituent at the core present in
aprepitant and netupitant is termed “arm 3”. Since CP-99,994
represents the progenitor antagonist on which many of the later
developed compounds were based (and as such makes only
limited contact to the receptor) the interactions of CP-99,994
within the NK1R binding site are described ﬁrst.
CP-99,994 speciﬁcally interacts with only seven residues from
helices III to VI and one residue from ECL2 in NK1R (Fig. 2a and
Supplementary Figure 3a). The core (2,3-cis-substituted-piper-
idine) is laterally wedged between the side chains of F2686.55
and Q1654.60 and capped by I182ECL2. Q1654.60 is positioned to
concomitantly hydrogen-bond the piperidine core and the amine
linker of arm 1. Mutation of Q1654.60 to either alanine, glutamic
acid or aspartic acid severely reduce the binding afﬁnity of CP-
99,994 (Fig. 2g). These data are in agreement with previous
studies reporting the critical nature of this interaction in binding
of CP-99,994 and other early non-peptide antagonists to NK1R35.
Mutation of F2686.55 to alanine attenuates binding afﬁnity
more than 10-fold36, highlighting the crucial nature of the
hydrophobic stacking interactions with the small-molecule core
moiety on this side of the orthosteric pocket.
Arm 1 of CP-99,994 extends deep into the receptor core,
exploiting a large, almost exclusively lipophilic groove at the base
of the orthosteric pocket formed by M2917.39, M2957.43, M812.53,
W2616.48, I2045.46, F2646.51 and P1123.32. Within this region,
the aromatic methoxyphenyl group of arm 1 is wedged between
F2646.51 and P1123.32 and sits above a deep protrusion into
the receptor core. The methoxy group points into a relatively
spacious extension of this pocket comprised of residues from
helices II, III and VII. Mutation of P1123.32 to either aspartic acid
or histidine results in a 4000-fold loss in binding afﬁnity of CP-
99,994 to NK1R36 with mutation of F2646.51 to alanine displaying
only a moderate (4-fold) impairment of binding35, highlighting
the importance of targeting this lipophilic local environment.
However, the importance of this sub-pocket is underlined by the
Table 1 Data collection and reﬁnement statistics
NK1R:CP-99,994a (PDB 6HLL) NK1R:aprepitanta (PDB 6HLO) NK1R:netupitanta (PDB 6HLP)
Data collection
Space group C2221 P212121 P212121
Cell dimensions
a, b, c (Å) 62.00, 122.73, 286.49 62.19, 76.45, 167.12 61.66, 76.57, 166.04
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Resolution (Å) 47.88–3.27 (3.53–3.27)b 48.24–2.40 (2.49–2.40)b 49.50–2.20 (2.27–2.20)b
Rmerge 0.689 (4.652) 0.188 (2.879) 0.161 (3.066)
Rpim 0.173 (1.225) 0.052 (0.795) 0.054 (1.035)
I/σ(I) 5.1 (1.1) 12.8 (1.7) 11.9 (1.3)
CC1/2 0.990 (0.311) 0.999 (0.753) 0.998 (0.666)
Completeness (%) 99.9 (99.6) 100.0 (100.0) 99.9 (99.4)
Redundancy 32.2 (29.6) 26.2 (26.4) 18.5 (18.8)
Reﬁnement
Resolution (Å) 24.92–3.27 29.44–2.40 29.24–2.20
No. of reﬂections (test set) 17,325 (874) 31,899 (1656) 40,668 (1997)
Rwork/Rfree 0.225/0.275 0.201/0.229 0.204/0.227
No. atoms
Protein 3754 3832 3882
Ligand 22 37 42
Water/ion/lipid – 355 475
B-factors
Protein 91.30 62.96 55.97
Ligand 87.89 54.13 51.20
Water/ion/lipid – 85.90 82.10
R.m.s. deviations
Bond lengths (Å) 0.004 0.003 0.004
Bond angles (°) 0.911 0.578 0.699
aThe structures of NK1R in complex with CP-99,994, aprepitant and netupitant were solved using X-ray diffraction data from 6, 6, and 5 crystals, respectively
bValues in parentheses are for highest-resolution shell
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introduction of a more bulky tryptophan at this position leading
to a >15-fold reduction in binding afﬁnity for CP-99,994 (Fig. 2g).
Arm 2 of CP-99,994 targets a second lipophilic sub-pocket,
making hydrophobic contacts to I1133.33 and V2005.42, and
is capped on top by a face-on π-stack with H1975.39. Mutation
of H1975.39 to alanine attenuates binding afﬁnity 3.5-fold, yet
preserving the aromatic character of this residue by virtue of
mutation to phenylalanine results in only a <2-fold reduction
in binding afﬁnity to the small molecule, supporting this observed
π-π interaction with the receptor.
Aprepitant, with its more extended structure due to its arm
3 substituent, engages in a host of additional interactions with
NK1R (Fig. 2b and Supplementary Figure 3b). The core of
aprepitant (2,3,4-substituted-morpholine) is situated between
F2686.55 and Q1654.60 and capped by a hydrophobic interaction
with I182ECL2 as in CP-99,994. However, Q1654.60 does not
contact the morpholine core, instead making hydrogen-bonds to
the oxygen atom of the arm 1 ether linker and a nitrogen atom
of the arm 3 substituent. The methyl substituent of the arm 1
ether linker then optimally targets a small lipophilic subpocket
formed between N1093.29, P1123.32 and I1133.33 on the surface
of helix III.
The aromatic ring of arm 1 is shifted upwards and sideways
towards helix II in comparison to CP-99,994. This arrangement
allows it to optimally exploit the hydrophobic base of this part of
the orthosteric pocket immediately above and adjacent to
W2616.48 by virtue of the 3,5-di-triﬂuoromethyl groups that
straddle the aromatic side chain of this residue. It is possible
that this direct engagement acts to prevent the activation-related
motion of W2616.48, thereby further stabilising NK1R in the
inactive conformation.
In a similar fashion to CP-99,994, arm 2 of aprepitant targets a
lipophilic subpocket formed by residues H1975.39, V2005.42,
T2015.43, I2045.46 and H2656.52. However, the additional arm
3 triazolinone substituent of aprepitant is found creating an
extended binding pocket (EBP) between the extracellular ends
of helices IV, V and VI and ECL2. Aprepitant can thus engage
an array of additional interactions with NK1R. The arm 2
(ﬂuorophenyl) and arm 3 (triazolinone) substituents of aprepitant
participate in a π-stacking interaction with H1975.39, while the
carbonyl group of the triazolinone group reaches up to hydrogen-
bond with the indole nitrogen of W184ECL2, with E1935.35
hydrogen-bonding to the N3 atom of the triazolinone ring. On
the other side of the triazolinone ring, the carbonyl group of
Q1654.60 makes a hydrogen bond with N5 of this 5-membered
ring. As a likely consequence of the additional network of
interactions that aprepitant makes to the receptor, the afﬁnity of
this small molecule is much less affected by single point
mutations in comparison to CP-99,994 (Fig. 2h). Mutation of
Q1654.60 to alanine, glutamic acid or aspartic acid only maximally
impairs binding <5-fold, in agreement with earlier ﬁndings
in which the mutant Q1654.60A displayed a 10-fold decrease in
binding afﬁnity for the close aprepitant analogue L-742,69423. In
contrast to CP-99,994, aprepitant therefore induces a conforma-
tional change of ECL2 and the extracellular ends of helix V and
VI, highlighting an unexpected high degree of plasticity across
this part of the receptor.
Both NK1R antagonists described thus far are based on the
chiral pharmacophore core of CP-99,994. In contrast, netupitant,
which was disclosed in 2006 and clinically approved in 201437,
belongs to a class of achiral, high-afﬁnity NK1R antagonists with
an aromatic pyridine core38. In a similar fashion to aprepitant,
netupitant adopts an elongated conformation inside the orthos-
teric binding site (Fig. 2c); however, it protrudes from the centre
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Fig. 1 Overall structures of antagonist-bound NK1R. a–c NK1R in complex
with CP-99,994 (a), aprepitant (b) and netupitant (c), viewed parallel to
the membrane plane. The receptors are depicted by ribbons and coloured in
brown, turquois and blue, respectively. The ligands CP-99,994, aprepitant
and netupitant are shown as spheres and coloured in pink, yellow and
orange, respectively. Oxygen, nitrogen and ﬂuorine atoms of the ligands are
highlighted in red, blue and grey, respectively. d–f NK1R in complex with
CP-99,994 (d), aprepitant (e) and netupitant (f), viewed from the
extracellular space and coloured as in (a–c). The ligands are depicted as
sticks. 2Fo-Fc electron density maps of the ligands are shown in green mesh
contoured at 1.0 σ
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of the orthosteric binding site towards extracellular space with
both its core and arm 3 substituent. The di-triﬂuoromethylphenyl
group of arm 1 and the methylphenyl group of arm 2 both target
the same hydrophobic pockets as the equivalent substituents of
the chiral antagonists. However, arm 2 is found to be in a more
“upright” position. Major deviations in the positioning of the core
region are observed within the orthosteric binding site, the linker
region of arm 1, and the arm 3 substituent.
Due to the elongated linker of arm 1, the aromatic core of
netupitant is pushed upwards and towards extracellular space
from the centre of the pocket (towards helices V and VI) (Fig. 2c
and Supplementary Figure 6c), while also moving sideways into
closer proximity of F2686.55. This observed repositioning of the
substituted pyridine towards helix V and in particular into closer
proximity of H1975.39 leads to an edge-to-face π-π interaction
between this side chain and the aromatic core. Consequently, the
importance of this aromatic interaction is reﬂected in a 10-fold
loss in netupitant binding afﬁnity upon mutation of H1975.39 to
alanine. In contrast, preserving the aromatic nature at this
position with a H1975.39F mutation leaves the binding afﬁnity
unchanged (Fig. 2i and Supplementary Table 1). In the
netupitant-bound NK1R structure, the side chain of Q1654.60 is
rotated by 180° (compared to all other structures), enabling the
water-mediated coordination of the oxygen atom of the amide
located in the arm 1 linker (Fig. 2c and Supplementary Figure 3c).
Furthermore, due to the different ligand position within the
binding site, arm 3 of netupitant targets a small hydrophobic
groove formed between residues F2686.55, P2716.58 and Y2726.59
at the extracellular tip of helix VI. The opening of this cleft
between two helical turns is supported by a slight outward
bending of the extracellular tip of helix VI towards the lipid
bilayer. Overall, with the exception of the direct π-π interaction
between the core and H1975.39, the additional interactions
between netupitant and NK1R render the afﬁnity of the
antagonist less affected by single point mutations when compared
to their inﬂuence on CP-99,994 binding afﬁnity (Fig. 2i).
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Fig. 2 Drug-binding site of NK1R. a–c Detailed interactions of CP-99,994 (a), aprepitant (b) and netupitant (c) with the receptor, viewed from the
extracellular side from a position above helix I. The receptor backbone is shown in grey ribbon representation. Ligand and receptor residues within 4 Å
of the respective antagonist are shown as sticks and are coloured as in Fig. 1. The ordered water involved in netupitant binding is depicted as a red sphere
(c). Hydrogen bonds are indicated by dashed blue lines. d–f Chemical structures of CP-99,994 (d), aprepitant (e) and netupitant (f) with structural
topology highlighted by coloured, dashed circles (core coloured in blue, arm 1 in yellow, arm 2 in green, arm 3 in red, respectively). g–i Antagonist afﬁnity
proﬁles of selected mutants in comparison to wild-type NK1R. pKi values for each antagonist were derived from competition ligand-binding experiments
(Supplementary Table 1). Bars represent differences in calculated afﬁnity (pKi) values for each mutant relative to the wild-type receptor for CP-99,994
(g), aprepitant (h), and netupitant (i). Data are shown as mean values ± s.e.m. from three to ﬁve independent experiments performed in duplicates. n.b. no
binding. Source Data
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Conformational changes induced by clinical NK1R antagonists.
The overall structure of netupitant-bound NK1R is similar to that
of the aprepitant-bound structure with an all-atom RMSD of
∼0.40 Å (Supplementary Figure 7a). However, both the aprepi-
tant- and netupitant-bound NK1R structures differ from the CP-
99,994-bound structure with all-atom RMSDs of ∼0.70 Å. In
comparison to the CP-99,994-bound receptor structure, aprepi-
tant induces structural rearrangements in the extracellular regions
of NK1R, and thus modulates the extracellular molecular land-
scape of the receptor (Fig. 3a and Supplementary Figure 7b): The
β-sheet of ECL2 is kinked away from the extracellular end of helix
III by 4.1 Å (as measured between equivalent Cα atoms of
T173ECL2), thereby accommodating an inward movement of helix
II and ECL1 by 1.7 Å (as measured between equivalent Cα atoms
of H952.67) and 2.1 Å (as measured between equivalent Cα atoms
of E97ECL1), respectively. In addition, the β-hairpin loop is itself
twisted towards the central axis of the receptor. This appears to
be related to the observed cis-conﬁguration of the peptide
bond preceding P175ECL2 located at the turn of the β-hairpin
(Supplementary Figure 7c–e), while a trans-proline is found in
the CP-99,994-bound structure. Together, these differences lead
to a slight contraction of the orthosteric binding pocket at the
helix II–IV interface of the receptor when binding aprepitant or
netupitant.
On the opposite side of the NK1R orthosteric hemisphere, the
extracellular end of helix V together with the C-terminal portion
of ECL2 is shifted 2.4 Å away from the central axis of the receptor
(as measured between equivalent Cα atoms of K190ECL2). This
shift is induced by the arm 3 substituent of aprepitant, which
creates an EBP at the interface between helices IV, V and ECL2,
thereby inducing signiﬁcant side-chain rearrangements on
this side of the receptor (Fig. 3a). The outward movement of
the C-terminal part of ECL2 starts at W184ECL2, which is pushed
3.5 Å out of the interhelical interface between helices IV and V by
the triazolinone group of aprepitant (Fig. 3f) in comparison to
the CP-99,994-bound structure. The outward push of W184ECL2
is accommodated by a 90° rotation of Y1925.34 towards the lipid
bilayer.
Further rearrangements caused by aprepitant are observed at
the extracellular portion of helices V and VI. Firstly, K1945.36
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Fig. 3 Conformational changes in NK1R induced by clinically used antagonists. a Superimposition of the CP-99,994- and aprepitant-bound NK1R structures,
viewed from helix I. Residues of NK1R with side-chain orientations differing between the two receptor structures as well as the antagonists are depicted as
sticks, coloured as in Fig. 1. b, c Hydrogen bond network connecting the extracellular ends of helices V and VI in the aprepitant- (b) and netupitant-bound
(c) NK1R structures as viewed from the membrane plane. Hydrogen bonds are indicated as dashed blue lines. d–f Close-up views on residues with differing
side-chain orientation in the CP-99,994- and the aprepitant-bound NK1R structure. Side-chain rearrangements from the CP-99,994- to the aprepitant-
bound conformation are indicated by black arrows
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is moved ~90° out of the orthosteric pocket, disengaging from
E1935.35 which is then free to hydrogen-bond the triazolinone
ring of aprepitant (Fig. 3e). Secondly, the side chain of H1975.39 is
rotated by ~90° out of the orthosteric pocket, while Y2726.59 at
the top of helix VI is moved by ~90° into the interface between
helices V and VI (Fig. 3d). This rearrangement of H1975.39 and
Y2726.59 causes the formation of an extended interhelical
hydrogen bond network connecting residues Y2726.59, H1975.39,
T2015.43 and H2656.52, thereby cross-linking the extracellular
ends of helices V and VI (Fig. 3b).
Although the arm 3 substituent of netupitant targets a part of
the receptor that is distinct from aprepitant (see above), both
antagonists are found to induce the same hydrogen bond network
by virtue of the reorientation of H1975.39 and Y2726.59 (Fig. 3b,
c). However, in contrast to aprepitant, in the case of netupitant,
the reorientation of H1975.39 is not caused solely by arm 3, but
rather by the different binding pose of the compound within the
orthosteric pocket, which shifts both the aromatic core and arm 2
into a position closer to helix V. This shift sterically precludes any
other rotameric orientation of H1975.39 except the one observed
in the crystal structure found engaged with the extended
hydrogen bond network.
Interestingly, H1975.39 has previously been linked to play a role
in insurmountable antagonism23. In that study, a single point
mutation of H1975.39 to serine was shown to alter the mode of
antagonism of a close aprepitant analogue (L-742,694, Supple-
mentary Figure 1) from insurmountable to surmountable while
only moderately affecting binding afﬁnity. Furthermore, it was
demonstrated that tethering of the tips on helix V and VI via
engineering of a high-afﬁnity metal ion-binding site involving
H1975.39 and two histidine residues introduced at position
E1935.35 and Y2726.59 rendered the receptor in an inactive
conformation39. Finally, this region of helix V, and rearrange-
ments of the hydrogen-bonding network between conserved
serines on helix V (speciﬁcally residues 5.42, 5.43 and 5.46 which
are a valine, threonine and isoleucine in NK1R, respectively) by
the catechol group of epinephrine in β1-AR and β2-AR further
points to the importance of this region on the extracellular side of
helix V in controlling the constellation of GPCR functional
states40,41.
It has long been acknowledged that interhelical hydrogen
bonds have a strong inﬂuence on the conformational stability of
membrane proteins42–44. The newly created hydrogen bond
network, in the aprepitant-bound and netupitant-bound struc-
tures, tethers helix V to helix VI (Fig. 3b, c). In particular certain
residues within the network have been shown to be critically
involved in GPCR receptor activation41,45,46. We thus hypothe-
sise that the reduction in conformational ﬂexibility through
engagement of the “histidine-lock” might represent a key driver
for the observed insurmountable antagonism that some com-
pounds such as aprepitant and netupitant elicit at NK1R.
Once the “histidine-lock” is engaged by structural rearrange-
ments induced by the mentioned insurmountable antagonists, the
receptor would be present in the proposed slow reversible
state47,48, while in the absence of tethering helices V and VI with
a hydrogen bond network only the fast reversible state would be
populated (as observed in the CP-99,994-bound NK1R structure).
Moreover, this structural differentiation might also be the basis of
the prolonged in vivo efﬁcacy of compounds such as aprepitant
and netupitant49,50: once the lock is engaged, the distinct
conformational state of the receptor may facilitate rebinding of
compounds without the need for conformational rearrangements,
thereby potentially increasing the effective association rate.
Structural basis of tight signaling control at NK1R. In the
available high-resolution structures of inactive class A GPCRs
where water molecules can be resolved, a conserved water-
mediated hydrogen bond network is found to connect helices II,
III, VI and VII51,52 (Supplementary Figure 8b–e). This network is
often clustered around a central sodium ion coordinated between
the highly conserved D2.50 and a polar residue on helix III (X3.39);
concomitantly, sodium has been extensively described as a
negative allosteric modulator stabilising the inactive receptor
conformation of class A GPCRs53,54.
D2.50 is highly conserved (98%) across all class A GPCRs, with
NK1R being one of the very few exceptions where an aspartic acid
is not present at this position55. In NK1R, this position is
occupied by a glutamate residue, E782.50 (Fig. 4a, b). Recent
functional studies56 suggest that this sequence variant is linked to
the unusual lack of constitutive signaling in NK1R27,36,57. The
high resolution of the netupitant-bound NK1R structure reported
here now provides a structural rationale for this observation.
E782.50 occupies a more central position in the water-mediated
hydrogen bond network compared to D2.50, making direct
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Fig. 4 E782.50-mediated interhelical hydrogen-bond network in the transmembrane core. a Amino acid sequence alignment of residues involved in the
allosteric sodium ion-binding site in NK1R and other class A GPCRs (Ballesteros-Weinstein numbers indicated). b, c Extracellular view on the hydrogen-
bonding network in the transmembrane core of netupitant-bound NK1R (b) and the dopamine D4 receptor (D4R, PDB ID 5WIV) (c). The receptor
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indicated by dashed blue lines. The sodium ion coordinated between D2.50 and S3.39 in the D4R is shown as a purple sphere
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hydrogen bonds to S1193.39 and N3017.49 of helices III and VII,
respectively (Fig. 4b). This stands in contrast to previously
reported GPCR structures, where the contact between the D2.50
carboxyl group and the side chain of X3.39 is mediated by the
aforementioned sodium ion58–61 (Supplementary Figure 8b–f) or
potentially a water molecule33. Importantly, these features occur
in addition to other conserved components of the network; for
example, there is still a water-mediated hydrogen bond between
the E782.50 side chain and the N3017.49 backbone nitrogen, as
well as another between N3017.49 and V2536.40, recapitulating the
interactions observed in the high-resolution D4R antagonist
structure58 (Fig. 4c). Finally, a water-mediated hydrogen bond
exists between helices I and II, through the side-chain oxygen
atom of N501.50 and the carboxyl group of E782.50, similar to the
interaction observed in several structures of other GPCRs such as
the δ-OR59, β1-AR60 and A2AR61 (Supplementary Figure 8c–e).
Therefore, it appears that the direct interactions mediated by
the larger glutamate side chain of NK1R at position X2.50 link the
helical bundle of NK1R together more tightly than an aspartic
acid would at the equivalent position, thus contributing to the
stability of the inactive state of NK1R. Importantly, a recent study
has shown that mutating E782.50 to aspartic acid results in a NK1
receptor phenotype which is susceptible to a similar sodium
concentration-dependent negative allosteric effect as many other
class A GPCRs56. Thus, E782.50 appears to almost assume the
functional role of the sodium ion in other GPCRs by virtue of one
single extra carbon atom—and in fact, may further enhance,
strengthen and expand the key sodium-mediated interactions in
providing a structural basis for the observed lack of basal
signaling in NK1R56.
Discussion
The crystal structures of NK1R with CP-99,994 (the progenitor
compound) and with aprepitant and netupitant, in use in the
clinic today for the treatment of CINV, reveal the structural basis
of the successful high-throughput screening and medicinal
chemistry campaigns directed towards this receptor spanning
several decades. To recapitulate, modiﬁcations of arm 1 and arm
2 substituents lead to a more optimal interaction with the narrow
orthosteric binding pocket, while the additional arm 3 substituent
present in aprepitant and netupitant allows these compounds to
induce a distinct receptor conformation by a potential induced-ﬁt
binding mechanism.
Additionally, the structures provide a possible molecular
rationale for the observed insurmountable antagonism of apre-
pitant and netupitant. These compounds create an inter-helical
hydrogen-bonding network at the extracellular ends of helices V
and VI, engaging a “histidine lock” in NK1R across a region
known a priori to be important in modulating activity for other
class A GPCRs. Finally, a mechanistic basis for the lack of basal
signaling of NK1R is provided by the network of hydrogen bonds
mediated by the unique residue E782.50 in the helical core of the
receptor, which overlaps the allosteric sodium binding site
observed in many inactive class A GPCR structures to date.
In light of the research presented here, it is now possible to
deploy structure-based drug-design methods for designing new
small molecules directed to NK1R, for the aforementioned indi-
cations. Furthermore, while the residues in the lower half of the
orthosteric pocket are largely conserved between NK1R, NK2R
and NK3R, sequence homology weakens towards the top of helix
V and VI between these closely related receptors. With careful
molecular modelling, coupled to molecular dynamics simulations,
the structure of NK1R now opens new avenues to design the next
generation of selective antagonists for the closely related NK2R
and NK3R, by speciﬁcally targeting this region at the top of
helices V and VI. The potential indications range from central
neurological disorders including major depressive disorder and
schizophrenia62,63, to vasomotor symptoms associated with the
menopause64. Additionally, endosome-targeted NK1R small-
molecule antagonists have recently been reported as pain relief
agents, presenting an alternative to opioid-based drugs18. Since
endosomal targeting as of now requires the coupling of the
antagonist to a lipophilic moiety, our results will aid the rational
design of new drugs in this class. In summary, the reported NK1R
structures greatly contribute to our knowledge and understanding
of how this clinically relevant family of receptors may be antag-
onised, providing opportunities to improve in vivo efﬁcacy and
reduce phase II attrition rates in the clinic for small-molecules
directed towards these receptors.
Methods
Generation of NK1R crystallisation construct. From a pool of previously pub-
lished NK1R mutants obtained by directed evolution in yeast for improved
expression levels29 using HiLyte Fluor 488-labeled Substance P, NK1R-y04
(V1163.36I, M181ECL2K, W2245.66R, ΔC336-407) was selected as a potential crys-
tallisation candidate since it could be well puriﬁed from Spodoptera frugiperda (Sf9)
insect cells as a monodisperse protein. However, NK1R-y04 displayed only limited
thermal stability in the CPM assay65 in complex with CP-99,994. To increase the
thermostability of NK1R-y04 in an antagonist-bound state, selected amino acids
within the transmembrane helical bundle were substituted with either alanine or
leucine (if the amino acid was an alanine). The resulting single mutants were
evaluated based on their gain in thermostability as evidenced by an increase in
melting temperature (Tm) in the CPM assay when puriﬁed in the presence of CP-
99,994. Single point-mutations which displayed the highest apparent gain in Tm
(L742.46A, A1444.39L, A2155.57L and K2436.30A) were subsequently combined
yielding the thermostabilised quadruple mutant NK1RS. Furthermore, to aid
crystallisation in lipidic cubic phase, eleven residues (E227-H237) of the ICL3 were
replaced by the thermostable PGS (Pyrococcus abysii glycogen synthase) domain,
yielding NK1RXTAL. The ﬁnal construct was cloned into a modiﬁed pFL vector
(MultiBac system, Geneva Biotech) resulting in an expression construct with a
melittin signal sequence followed by a FLAG-tag, His10-tag and a human rhino-
virus 3C protease cleavage site N-terminal to the receptor gene (all primers used in
this study are listed in Supplementary Table 2).
Expression and puriﬁcation of NK1R. Recombinant baculovirus was generated
using the MultiBac expression system. The receptor expression cassettes were
integrated into the DH10EMBacY baculovirus genome and the resulting bacmids
were transfected into Sf9 cells in 6-well tissue culture plates (2 ml, density of 4 × 105
cells/ml) using 8 μl of Cellfectin II Reagent (Thermo Fisher Scientiﬁc) and Sf-900 II
SFM medium (Thermo Fisher Scientiﬁc). Viral P0 stocks were harvested as the
supernatant after 4 days and were subsequently ampliﬁed to obtain high-titer viral
P1 stocks. For expression, Sf9 insect cells in Sf-900 II SFM medium were infected
with P1 virus at a cell density of 3 × 106 cells/ml and a multiplicity of infection of 5.
Expression was performed for 72 h at 27 °C under constant shaking. Cells were
harvested by centrifugation, washed with PBS, frozen in liquid nitrogen and stored
at −80 °C.
Insect cells expressing NK1RXTAL were lysed and receptor-containing
membranes isolated by repeated Dounce homogenisation in hypotonic (10 mM
HEPES pH 7.5, 20 mM KCl, 10 mM MgCl2, 50 µg/ml Pefabloc SC (Carl Roth),
1 µg/ml Pepstatin A(Carl Roth)) and hypertonic buffer (10 mM HEPES pH 7.5,
20 mM KCl, 10 mM MgCl2, 1.0 M NaCl, 50 µg/ml Pefabloc SC, 1 µg/ml Pepstatin
A). Puriﬁed membranes were resuspended in 30 ml hypotonic buffer supplemented
with 40 µM of the respective antagonist (CP-99,994 (Tocris)/aprepitant (Sigma
Aldrich)/netupitant (Selleckchem)), frozen in liquid nitrogen and stored at −80 °C
until further use.
Frozen membranes were thawed on ice, the respective ligand (CP-99,994,
aprepitant or netupitant) was added to a ﬁnal concentration of 80 µM and the
suspension was incubated for 30 min while turning. 2 mg/ml iodoacetamide (Sigma
Aldrich) was added to the solution followed by another 30 min of incubation.
Subsequently, the receptor was solubilised in 30 mM HEPES pH 7.5, 500 mM
NaCl, 10 mM KCl, 5 mM MgCl2, 50 µg/ml Pefabloc SC, 1 µg/ml Pepstatin A, 1%
(w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace) and 0.2% (w/v)
cholesteryl hemisuccinate (CHS, Sigma Aldrich) at 4 °C for 3 h. Insoluble material
was removed by ultra-centrifugation and the supernatant was incubated with
TALON IMAC resin (GE Healthcare) at 4 °C overnight.
The receptor-bound resin was washed with 30 column volumes (CV) of Wash
Buffer I (50 mM HEPES pH 7.5, 500 mM NaCl, 10 mM MgCl2, 5 mM imidazole,
10% (v/v) glycerol, 1.0% (w/v) DDM, 0.2% (w/v) CHS, 8 mM ATP, 40 µM CP-
99,994/20 µM aprepitant/20 µM netupitant) followed by 30 CV of Wash Buffer II
(50 mM HEPES pH 7.5, 500 mM NaCl, 15 mM imidazole, 10% (v/v) glycerol,
0.05% (w/v) DDM, 0.01% (w/v) CHS, 40 µM CP-99,994/20 µM aprepitant/20 µM
netupitant). Antagonist-bound NK1R was eluted step-wise with four column
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volumes of Elution Buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 250 mM
imidazole, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 100 µM CP-
99,994/50 µM aprepitant/50 µM netupitant). Protein-containing fractions were
concentrated to 0.5 ml using a 100 kDa molecular weight cut-off Vivaspin 2
concentrator (Sartorius Stedim) and added to a PD MiniTrap G-25 column (GE
Healthcare) equilibrated with G25 Buffer (50 mM HEPES pH 7.5, 500 mM NaCl,
10% (v/v) glycerol, 0.03% (w/v) DDM, 0.006% (w/v) CHS, 100 µM CP-99,994/
50 µM aprepitant/50 µM netupitant) to remove imidazole. The complex was
treated for 6 h with His-tagged 3C protease and PNGaseF (both prepared in-house)
to remove the N-terminal afﬁnity tags and deglycosylate the receptor. After
incubation with Ni-NTA resin (GE Healthcare) overnight, cleaved receptor was
collected as the ﬂow-through and then concentrated to ~50–60 mg/ml with a
100 kDa molecular weight cut-off Vivaspin 2 concentrator. Protein concentrations
were determined by absorbance at 280 nm on a Nanodrop 2000 spectrophotometer
(Thermo Fisher Scientiﬁc). Protein purity and monodispersity were assessed by
SDS-PAGE and analytical size-exclusion chromatography using a Sepax Nanoﬁlm
SEC-250 column.
Crystallisation in lipidic cubic phase. NK1R was crystallised using the in meso
method at 20 °C. For this purpose, concentrated protein (~50–60 mg/ml) was
mixed with molten monoolein (Sigma Aldrich) supplemented with 10% (w/w)
cholesterol (Sigma Aldrich) using the twin-syringe method. The ﬁnal protein:
lipid ratio was 40:60 (v/v). 40 nl boli were dispensed on 96-well glass bases with
a 120 µm spacer (SWISSCI), overlaid with 800 nl precipitant solution using a
Gryphon LCP crystallisation robot (Art Robbins Instruments) and sealed with a
cover glass. In initial screens of CP-99,994-bound NK1R, crystals appeared after
less than 1 h in a broad range of conditions. Optimised crystals used for data
collection were grown in a precipitant condition consisting of 100 mM MES pH
6.0, 31% (v/v) PEG400, 190–210 mM potassium acetate, 2.4% (v/v) 2,5-hexanediol
and 50 µM CP-99,994. Aprepitant-bound NK1R yielded much fewer initial
crystallisation hits compared to CP-99,994-bound NK1R. Optimised star-shaped
crystals used for data collection of aprepitant-bound NK1R were obtained in a
condition consisting of 100 mM sodium citrate pH 6.0, 31% (v/v) PEG400,
50–70 mM MgCl2 and 50 µM aprepitant. Crystals used for data collection of
netupitant-bound NK1R were obtained in a condition consisting of 100 mM
sodium citrate pH 6.0, 31% (v/v) PEG400, 40–50 mM Mg(HCO2)2 and 50 µM
netupitant. Single crystals were mounted with Dual-Thickness MicroMounts
(MiTeGen) of appropriate size for data collection and cryo-cooled in liquid
nitrogen without the addition of further cryoprotectant.
Data collection and structure determination. X-ray diffraction data were
collected at the X06SA beamline at the Swiss Light Source (SLS) of the Paul
Scherrer Institute (PSI, Villigen, Switzerland) using a beam size of 10 × 10 μm and
an EIGER 16M detector. Datasets for CP-99,994-bound NK1R were collected using
a beam attenuated to 10%, 0.1° of oscillation and 0.1 s exposure time. All other
datasets were collected using a beam attenuated to 30%, 0.1° of oscillation and
0.05 s exposure time. Data from individual crystals were integrated using XDS66.
Data merging and scaling was carried out using the program AIMLESS from the
CCP4 suite67,68. Data collection statistics are reported in Table 1.
Initial phases were obtained by molecular replacement (MR) with the
program Phaser69 using the truncated OX2R transmembrane domain (PDB ID
4S0V) and the separated PGS fusion protein31 as independent search models
looking for one copy of each domain. Manual model building was performed
in COOT70 using sigma-A weighted 2m|Fo|-|DFc|, m|Fo|-D|Fc| maps together
with simulated-annealing and simple composite omit maps calculated using
Phenix71. Initial reﬁnement was carried out with REFMAC572 using maximum-
likelihood restrained reﬁnement in combination with the jelly-body protocol.
Further and ﬁnal stages of reﬁnement were performed with Phenix.reﬁne73
with positional, individual isotropic B-factor reﬁnement and TLS. The ﬁnal
reﬁnement statistics are presented in Table 1. Co-ordinates and structure factors
have been deposited in the worldwide Protein Data Bank under accession codes
6HLL, 6HLO and 6HLP for the CP-99,994-, aprepitant- and netupitant-bound
NK1R, respectively.
Whole-cell ligand-binding assay. HEK293T/17 cells (ATCC) were cultivated in
Dulbecco’s modiﬁed medium (Sigma) supplemented with 100 units/ml penicillin,
100 µg/ml streptomycin (Sigma) and 10% (v/v) foetal calf serum (BioConcept).
Cells were maintained at 37 °C in a humidiﬁed atmosphere of 5% CO2, 95% air.
Transient transfections were performed with TransIT-293 (Mirus Bio) according to
the manufacturer’s instructions.
Ligand-binding experiments were performed on whole HEK293T cells for
comparison of afﬁnities for wild-type and receptor mutants using a homogeneous
time-resolved ﬂuorescence (HTRF) binding assay. Receptor mutants were
generated by site-directed mutagenesis and cloned into a mammalian expression
vector (pcDNA3.1(+)) containing an N-terminal SNAP-tag (Cisbio).
HEK293T cells were transiently transfected with receptor constructs and were
seeded at 20,000 cells per well in poly-L-lysine-coated 384-well plates (Greiner).
Forty-eight hours after transfection, cells were labelled with 50 nM SNAP-Lumi4-
Tb (Cisbio) in assay buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 3 mM MgCl2
and 0.2% (w/v) nonfat milk) for 1.5 h at 37 °C. Cells were washed four times with
assay buffer and were then incubated for 2 h at RT in assay buffer containing
ﬂuorescently labelled peptide SP-HL488 (Substance P labelled with HiLyte Fluor
488 at Lys-3 (Anaspec))29. For competition binding, 20 nM of SP-HL488 tracer
peptide and a concentration range of unlabelled antagonists as competitor were
used. Fluorescence intensities were measured on an Inﬁnite M1000 ﬂuorescence
plate reader (Tecan) with an excitation wavelength of 340 nm and emission
wavelengths of 620 nm and 665 nm for Tb3+ and the ﬂuorophore HiLyte Fluor
488, respectively. The ratio of FRET-donor and acceptor ﬂuorescence intensities
(F665 nm/F620 nm) was calculated. Total binding was obtained in the absence of
competitor, and nonspeciﬁc binding was determined in the presence of 100 μM
unlabelled competitor. Data were normalised to the speciﬁc binding for each
individual experiment and were analysed by global ﬁtting to a one-site
heterologous competition equation with the GraphPad Prism software (version
6.07, GraphPad). To obtain Ki values, data were corrected for ﬂuorescent ligand
occupancy of each mutant with the Cheng-Prusoff equation as Ki= IC50/(1+
[ﬂ. ligand]/Kd).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates and structure factors have been deposited in the Protein Data
Bank under accession codes 6HLL, 6HLO and 6HLP for the CP-99,994-, aprepi-
tant- and netupitant-bound NK1R, respectively. Data supporting the ﬁndings of
this manuscript are available from the corresponding author upon reasonable
request. The source data underlying Fig. 2 and Supplementary Table 1 are provided
as a Source Data ﬁle.
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